Skip to main content

Alecnib 150 mg ( Alectinib)

Alecnib 150 mg is identified on this website as a product containing alectinib, an oral targeted anticancer medicine used for certain patients with ALK-positive non-small cell lung cancer (NSCLC).

Alectinib belongs to a group of medicines called anaplastic lymphoma kinase (ALK) inhibitors. It works by blocking abnormal ALK signaling involved in the growth and survival of certain cancer cells.

Like other prescription anticancer medicines, alectinib can cause side effects. Some reactions may be mild or manageable, while others can be serious and require immediate medical assessment.

Understanding possible side effects helps patients recognize warning signs, communicate with their healthcare team, and follow an appropriate monitoring plan.

Important: The information below describes adverse reactions associated with alectinib, primarily using the reference product Alecensa prescribing information. It does not establish the exact side-effect profile of every product sold as Alecnib.

1. What Are the Common Side Effects of Alectinib?

Patients receiving alectinib may experience different side effects depending on their health, treatment duration, dosage, and individual response.

Commonly reported adverse reactions include:

  • Fatigue or tiredness.
  • Constipation.
  • Muscle pain.
  • Swelling in the hands, feet, or other areas.
  • Nausea.
  • Rash.
  • Cough.
  • Changes in liver enzyme levels.
  • Changes in blood test results.

Not every patient experiences these effects. Some patients may have only mild symptoms, while others may require medical assessment or treatment modification.

Patients should inform their healthcare professional about persistent or troublesome symptoms.

2. Fatigue and Tiredness

Fatigue is a commonly reported adverse reaction during alectinib treatment.

Patients may feel unusually tired, weak, or less energetic than usual. Fatigue can affect everyday activities, work, sleep, and physical activity.

Possible symptoms

  • Persistent tiredness.
  • Reduced energy.
  • Difficulty concentrating.
  • Feeling physically weak.
  • Reduced ability to perform usual activities.

General management

Patients may find the following measures helpful:

  • Maintain a regular sleep schedule.
  • Take appropriate rest periods.
  • Eat balanced meals when possible.
  • Maintain adequate fluid intake.
  • Perform gentle physical activity if medically appropriate.
  • Inform the healthcare team if fatigue becomes persistent or severe.

Severe or unexplained fatigue should be assessed because it may also be associated with anemia, liver problems, or other medical conditions.

3. Constipation

Constipation is another commonly reported side effect of alectinib.

It may involve less frequent bowel movements, hard stools, abdominal discomfort, or difficulty passing stools.

Possible symptoms

  • Infrequent bowel movements.
  • Hard or dry stools.
  • Bloating.
  • Abdominal discomfort.
  • Straining during bowel movements.

General management

Depending on the patient’s medical condition, helpful measures may include:

  • Drinking adequate fluids.
  • Eating fiber-containing foods.
  • Maintaining gentle physical activity.
  • Following a regular bathroom routine.
  • Discussing suitable constipation treatments with a healthcare professional.

Patients should seek medical advice if constipation becomes severe or is accompanied by significant abdominal pain, vomiting, or inability to pass stool or gas.

4. Muscle Pain and Myalgia

Muscle pain, also known as myalgia, can occur during alectinib treatment.

Some patients experience mild discomfort, while others may develop more significant muscle tenderness or weakness.

Possible symptoms

  • Muscle soreness.
  • Tenderness.
  • Unexplained muscle pain.
  • Muscle weakness.
  • Difficulty performing normal physical activities.

Alectinib may also cause increased creatine phosphokinase (CPK), a blood marker that can indicate muscle injury.

What should patients do?

Patients should report unexplained muscle symptoms to their oncologist.

The healthcare professional may arrange a CPK blood test and assess whether treatment modification is necessary.

Severe muscle pain, significant weakness, or dark-colored urine requires prompt medical evaluation.

5. Swelling and Edema

Swelling, medically known as edema, can occur during alectinib treatment.

It may affect the feet, ankles, hands, or other areas of the body.

Possible symptoms

  • Swollen ankles.
  • Puffy feet.
  • Swelling of the hands.
  • Tightness around affected areas.
  • Discomfort when wearing shoes or clothing.

Patients should report new or worsening swelling, particularly if it develops suddenly or affects breathing.

Swelling can have several possible causes, including medication effects, kidney problems, or cardiovascular conditions. A healthcare professional should determine the underlying cause.

6. Nausea

Nausea is a possible adverse reaction during alectinib treatment.

Patients may experience an unsettled stomach, reduced appetite, or discomfort after eating.

General management

  • Follow the prescribed administration instructions.
  • Take the reference Alecensa formulation with food.
  • Eat smaller meals if this helps.
  • Avoid foods that worsen nausea.
  • Maintain adequate hydration.
  • Discuss persistent nausea with the healthcare team.

Patients should not take additional doses if vomiting occurs after a dose of the reference Alecensa product. The next dose should be taken at the regularly scheduled time.

Repeated vomiting should be reported to a healthcare professional.

7. Rash and Skin Reactions

Some patients may develop a rash during alectinib treatment.

Skin reactions may appear in different forms and can vary in severity.

Possible symptoms

  • Redness.
  • Itching.
  • Small raised bumps.
  • Skin irritation.
  • Dryness.
  • Localized skin discomfort.

Patients should report persistent or worsening skin reactions.

A widespread rash, blistering, peeling skin, facial swelling, or rash accompanied by fever requires urgent medical assessment because it may indicate a serious reaction.

8. Liver Enzyme Elevation and Liver Injury

Alectinib can affect liver function and may cause increased liver enzyme levels.

In some patients, serious liver injury may occur.

Possible warning signs

  • Yellowing of the skin or eyes.
  • Dark urine.
  • Unusual tiredness.
  • Abdominal discomfort.
  • Loss of appetite.
  • Persistent nausea.
  • Abnormal liver blood test results.

Some patients may not experience noticeable symptoms during early liver enzyme changes.

Monitoring requirements

For the reference Alecensa product, liver function tests, including ALT, AST, and total bilirubin, are recommended every two weeks during the first three months of treatment, followed by monthly testing and additional testing when clinically indicated.

The healthcare professional may recommend treatment interruption or dosage modification if significant liver abnormalities develop.

Patients should not independently stop or reduce their medicine.

9. Bradycardia and Slow Heart Rate

Alectinib may cause bradycardia, a condition in which the heart beats more slowly than normal.

Some patients may have no symptoms. Others may experience dizziness, weakness, or fainting.

Possible symptoms

  • Dizziness.
  • Light-headedness.
  • Unusual tiredness.
  • Weakness.
  • Fainting.
  • Reduced exercise tolerance.

Patients should tell their doctor if they have a history of heart rhythm problems or take medicines that reduce heart rate.

Healthcare professionals may monitor heart rate and blood pressure during treatment.

Fainting, severe dizziness, or chest discomfort requires urgent medical assessment.

10. Interstitial Lung Disease and Pneumonitis

Alectinib may cause interstitial lung disease (ILD) or pneumonitis, involving inflammation of lung tissue.

These conditions can affect breathing and may become serious.

Warning symptoms

  • New or worsening cough.
  • Shortness of breath.
  • Difficulty breathing.
  • Fever.
  • Unexplained respiratory discomfort.
  • Reduced ability to perform normal physical activities.

Patients should promptly report new or worsening respiratory symptoms.

If lung inflammation is suspected, the healthcare professional may arrange investigations and decide whether treatment interruption or discontinuation is necessary.

Emergency warning

Severe breathing difficulty requires immediate emergency medical attention.

11. Kidney-Related Adverse Reactions

Kidney impairment has been reported during alectinib treatment, including serious cases.

The kidneys help remove waste products and maintain fluid balance. Changes in kidney function may affect overall health and require medical attention.

Possible warning signs

  • Reduced urine output.
  • Unusual swelling.
  • Persistent nausea.
  • Unexplained weakness.
  • Changes in fluid balance.

Healthcare professionals may arrange kidney function tests when clinically appropriate.

Patients with existing kidney disease should discuss their condition before beginning treatment.

12. Hemolytic Anemia

Hemolytic anemia occurs when red blood cells are destroyed faster than the body can replace them.

This reaction has been reported during alectinib treatment.

Possible symptoms

  • Unusual tiredness.
  • Weakness.
  • Pale skin.
  • Dizziness.
  • Shortness of breath during activity.
  • Yellowing of the skin or eyes in some cases.

Patients experiencing these symptoms should contact their healthcare professional.

Blood tests may be required to investigate anemia and possible red blood cell destruction.

13. Increased Triglycerides and Pancreatitis

Alectinib may cause increased triglyceride levels in the blood.

Triglycerides are a type of fat circulating in the bloodstream. Very high levels can increase the risk of complications, including pancreatitis.

Possible warning signs of pancreatitis

  • Severe abdominal pain.
  • Persistent nausea.
  • Repeated vomiting.
  • Significant abdominal discomfort.

The reference Alecensa prescribing information recommends checking triglyceride levels before treatment and periodically during therapy.

Severe or persistent abdominal pain should be assessed promptly.

14. Other Possible Side Effects

Additional adverse reactions may occur during alectinib treatment.

These may include:

  • Headache.
  • Changes in appetite.
  • Cough.
  • Gastrointestinal discomfort.
  • Changes in blood test results.
  • Weight changes.
  • Other symptoms reported during clinical treatment.

The type and severity of reactions differ between patients.

A complete list of possible adverse reactions should be obtained from the applicable official prescribing information.

15. Which Side Effects Require Immediate Medical Attention?

Certain symptoms may indicate a serious complication and should not be ignored.

Seek urgent medical attention

  • Severe breathing difficulty or worsening shortness of breath.
  • Fainting or loss of consciousness.
  • Severe dizziness with weakness.
  • Yellowing of the skin or eyes with other concerning symptoms.
  • Severe muscle pain or significant weakness.
  • Severe abdominal pain with persistent vomiting.
  • Signs of a serious allergic reaction, including swelling of the face or throat.
  • Severe or rapidly worsening symptoms.This is not a complete list of emergencies. Follow local emergency medical guidance.

16. Can Side Effects Become More Severe Over Time?

Side effects may develop at different times during treatment.

Some reactions may occur early, while others may appear after a longer period of medicine use.

The severity of an adverse reaction can depend on:

  • Individual sensitivity to the medicine.
  • Treatment duration.
  • Existing medical conditions.
  • Other medicines being used.
  • Changes in liver or kidney function.
  • Individual treatment response.

Patients should continue attending scheduled appointments even when they feel well.

New symptoms should be reported rather than assumed to be unrelated to treatment.

17. How Are Alectinib Side Effects Managed?

Management depends on the type and severity of the adverse reaction.

A healthcare professional may recommend:

  • Clinical examination.
  • Blood tests.
  • Heart rate and blood pressure assessment.
  • Kidney function evaluation.
  • Imaging or other investigations.
  • Symptom-specific treatment.
  • Temporary treatment interruption.
  • Dose reduction.
  • Permanent treatment discontinuation when necessary.

The decision depends on the applicable prescribing information and the patient’s clinical circumstances.

Patients should never independently change their dose to manage side effects.

18. Monitoring to Detect Side Effects Early

Regular monitoring helps healthcare professionals identify possible complications before they become more serious.

Monitoring test or assessmentPurpose
ALT, AST, and bilirubinEvaluate liver function
CPK blood testInvestigate possible muscle injury
Heart rateDetect slow heart rate
Blood pressureSupport cardiovascular assessment
TriglyceridesIdentify elevated blood fat levels
Kidney functionAssess possible renal impairment
Blood testsInvestigate suspected anemia
Respiratory assessmentEvaluate possible lung inflammation
Clinical examinationsAssess overall treatment tolerance

For the reference Alecensa product, liver function tests and CPK monitoring follow the schedules described in its prescribing information. The treating clinician may recommend additional monitoring.

19. Can Patients Prevent Alectinib Side Effects?

Not all adverse reactions can be prevented. However, following the prescribed treatment plan and attending regular monitoring appointments can help identify problems early.

Patients can support safer treatment by:

  • Taking the medicine exactly as prescribed.
  • Following the applicable food instructions.
  • Attending recommended laboratory tests.
  • Reporting new symptoms promptly.
  • Avoiding unapproved medicines or supplements.
  • Informing the healthcare team about all current medicines.
  • Following pregnancy and breastfeeding precautions.
  • Maintaining adequate hydration and nutrition when possible.
  • Avoiding independent dosage changes.

Patients should remember that a targeted medicine can still cause serious adverse reactions.

20. Who May Have a Higher Risk of Complications?

Some patients may need additional monitoring or precautions.

These include individuals with:

  • Existing liver disease.
  • Kidney impairment.
  • Heart rhythm conditions.
  • Previous muscle disorders.
  • Respiratory or lung conditions.
  • Anemia or other blood-related disorders.
  • Multiple concurrent medications.
  • Pregnancy or potential pregnancy.

These conditions do not automatically mean that alectinib cannot be used. A qualified healthcare professional must evaluate the benefits and risks.

21. What Should Patients Do If Side Effects Affect Daily Life?

Treatment-related symptoms may interfere with normal activities, sleep, appetite, or physical comfort.

Patients should discuss these problems with their healthcare team.

Useful information to provide includes:

  • The symptom being experienced.
  • When it started.
  • How frequently it occurs.
  • Whether it is becoming worse.
  • Whether it affects eating, sleeping, or daily activities.
  • Other medicines being taken.
  • Any previous treatment-related problems.

Keeping a symptom record may help the healthcare professional assess the situation and recommend appropriate care.

22. Do All Patients Experience the Same Side Effects?

No. Alectinib affects patients differently.

Some people may tolerate treatment with relatively few noticeable symptoms, while others may experience multiple adverse reactions.

The likelihood and severity of side effects depend on individual health, treatment exposure, other medicines, and other clinical factors.

A patient should not compare their treatment experience directly with another person’s experience or change their medicine based on someone else’s symptoms.

23. Important Side-Effect Questions

Does Alecnib cause hair loss?

Hair loss is not among the principal common adverse reactions highlighted in the reference Alecensa prescribing information. However, individual experiences may vary. Patients should discuss unexpected hair changes with their healthcare professional.

Can alectinib cause weight gain?

Swelling and edema may occur during treatment and can affect body weight. Other factors may also contribute to weight changes. Sudden or unexplained weight gain should be discussed with a doctor.

Can alectinib cause stomach problems?

Yes. Gastrointestinal symptoms such as constipation and nausea have been reported. Severe abdominal pain or persistent vomiting requires medical assessment.

Can alectinib cause muscle weakness?

Yes. Muscle pain and muscle-related abnormalities may occur. Unexplained weakness or tenderness should be reported because it may indicate muscle injury.

Can alectinib affect the heart?

Alectinib may slow the heart rate. Patients should report fainting, dizziness, or unusual weakness and attend recommended heart-rate monitoring.

Should patients stop treatment if side effects occur?

Patients should not stop treatment independently. They should contact their healthcare professional, who can determine whether treatment should continue, be interrupted, reduced, or discontinued.

Are all side effects permanent?

No. Some adverse reactions may improve with appropriate management, while others may require treatment modification. Recovery depends on the specific reaction and the patient’s health.

Can side effects occur after months of treatment?

Yes. Adverse reactions may develop at different stages of therapy. Regular monitoring remains important throughout treatment.

Important Medical Disclaimer

This page provides general educational information about possible adverse reactions associated with alectinib. It is not a complete list of side effects and does not replace the official prescribing information or professional medical advice.

Alecnib is identified on this website as a product containing alectinib in a stated strength of 150 mg. Its manufacturer, formulation, regulatory status, and product-specific safety information should be independently confirmed.

The side-effect information presented here is based primarily on the reference product Alecensa and may not apply identically to every alectinib product or country.

Always consult your treating oncologist before making changes to your medicine. Seek urgent medical attention for severe or potentially life-threatening symptoms.